Icosai biology completed round B financing of more than RMB 100 million and made great efforts to build a Chinese core for cell culture

Yiouda health on October 27, recently, icosai biology announced the completion of round B financing of more than 100 million yuan. This round of financing is led by Jingwei venture capital and followed by CICC Qichen fund, Kangjun capital and other institutions under CICC capital. It is mainly used for the construction of production capacity and R & D center to accelerate the localization of key raw material technologies for cell culture. Founded in 2006, with the mission of "accelerating the application of life technology and benefiting people's health", excell bio is committed to solving the problem of biomedical neck sticking and realizing the localization of key raw materials. Now it has become one of the leading enterprises in the upstream core raw materials of biomedicine in China. At present, the company focuses on three product segments: serum-free medium, fetal bovine serum and identification reagent to provide international quality products and services for customers of biological drugs, cell and gene therapy and basic scientific research. Relying on the international and professional R & D technology team, quality and production team and commercialization team, the company continues to innovate and pursue excellence. While continuously optimizing product performance, the company ensures reliable quality and stable supply, comprehensively enables the rapid and healthy development of biomedical industry, and creates cell culture "Chinese core" products.